Topiramate Capsule, Extended Release
Product Images NDC 27241-296

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 27241-296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg (Topiramate 100mg)

100mg (Topiramate 100mg)
This is a description of topiramate extended-release capsules with a dosage of 100 mg per capsule. The recommended dosage is to be administered once daily. Store in a tight container at a temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The package is child-resistant and should be kept out of reach of children. This medication is distributed by Ajanta Pharma USA Inc. from Bridgewater, NJ, but it is manufactured in India. Each package contains 30 capsules for once-daily dosing. Pharmacists are required to dispense the accompanying Medication Guide to each patient.*
FDA Label Image

150mg (Topiramate 150mg)

150mg (Topiramate 150mg)
This is a medication description for topiramate extended-release capsules containing 150mg of topiramate, USP. The recommended dosage is to administer one dose daily. It should be stored between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F) and protected from moisture in a child-resistant package. The medication is manufactured by Ajanta Pharma USA Inc., and is made in India. The NDC number is 27241-299-30, with 30 capsules in each package. Pharmacies are advised to dispense the accompanying Medication Guide to each patient.*
FDA Label Image

200mg (Topiramate 200mg)

200mg (Topiramate 200mg)
This text provides information about extended-release capsules containing topiramate 200 mg. The recommended dosage is once daily. It includes instructions for storage, such as keeping in a tight container at a specific temperature range and protecting from moisture. The package is child-resistant, and it is advisable to keep it out of reach of children. The product is marketed by Ajanta Pharma USA Inc., made in India. It also mentions a specific NDC number for identification and advises pharmacists to dispense the accompanying Medication Guide to each patient.*
FDA Label Image

25mg (Topiramate 25mg)

FDA Label Image

50mg (Topiramate 50mg)

50mg (Topiramate 50mg)
This text provides information about topiramate extended-release capsules, each containing 50 mg of topiramate. The recommended dosage is once daily. The capsules should be stored in a tight container at room temperature, protected from moisture. It is child-resistant and should be kept out of reach of children. The product is marketed by Ajanta Pharma USA Inc. and made in India. Pharmacists are instructed to dispense the accompanying Medication Guide to each patient. The NDC code is 27241-297-30, and there are 30 capsules in the package.*
FDA Label Image

Figure1 (Topiramate Figure1)

FDA Label Image

Figure2 (Topiramate Figure2)

Figure2 (Topiramate Figure2)
This text provides a breakdown of the proportion of patients experiencing a reduction in seizure frequency from baseline while taking a placebo or 200mg/day of Topiramate. The data is presented in percentage terms ranging from 0% to 100%. It also includes categories for patients experiencing worsening of seizures.*
FDA Label Image

Figure3 (Topiramate Figure3)

Figure3 (Topiramate Figure3)
This text discusses the change from baseline to double-blind phase in average monthly migraine per patient based on different medication dosages (placebo, 50mg/day, 100mg/day, and 200mg/day). The study is labeled as Study 11 and Study 12, with statistical significance denoted as p<0.010 for one case and p<0.001 for another. The specific details and findings of the study are not provided in the given text.*
FDA Label Image

Structure (Topiramate Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.